Can one weekly shot fix both blood sugar and weight in type 2 diabetes?
In this phase 3a trial, a once-weekly injection called CagriSema lowered HbA1c by 1.7 percentage points more than placebo and reduced body weight by 13.8 percent over 40 weeks. The 189 adults enrolled all had type 2 diabetes that diet and exercise alone were not controlling.
That matters for two reasons. Type 2 diabetes is a problem of high blood sugar, and in this trial the average participant carried substantial extra weight, with a mean BMI of 35.2 kg/m2 at the start. This study suggests one weekly injection can move both numbers at once.
How CagriSema works
CagriSema combines two medicines in a single shot. One is semaglutide, a GLP-1 receptor agonist that many people already know from diabetes and weight-loss treatments. The other is cagrilintide, an amylin receptor agonist, which acts on the pathway of a natural hormone involved in signalling fullness.
These two work on different receptors. GLP-1 drugs help the body release insulin and slow how fast the stomach empties. The amylin side adds a separate fullness signal. The trial tested the two together as a single novel combination rather than comparing each drug on its own.
What the data show
The trial ran at 42 sites across six countries and randomly assigned participants to CagriSema at 2.4 mg of each component, CagriSema at 1.0 mg of each component, or matching placebo, for 40 weeks. Baseline mean HbA1c was 7.8 percent.
On the top dose, HbA1c fell by 1.8 percentage points, compared with a 0.1 percentage-point fall on placebo. That works out to a placebo-adjusted difference of 1.7 percentage points, with a 95 percent confidence interval running from 1.3 to 2.0 percentage points and a p value below 0.0001. The lower dose dropped HbA1c by 1.5 percentage points, a difference of 1.3 percentage points versus placebo.
Body weight followed the same pattern. Participants on the top dose lost 13.8 percent of their body weight, against 1.4 percent on placebo, a difference of 12.4 percentage points. The lower dose produced an 11.8 percent loss, a difference of 10.4 percentage points. Both comparisons reached p below 0.0001.
Side effects were common but generally not severe. Adverse events were reported by 79 percent of the top-dose group, 75 percent of the lower-dose group, and 66 percent of the placebo group. Most were mild or moderate and gastrointestinal in nature, which is what I would expect from a drug acting on these pathways.
Dr. Kumar’s Take
The size of the effect here is what makes this trial worth reading. Cutting HbA1c by nearly two percentage points while taking off close to 14 percent of body weight, from a single weekly injection, is a large result for a population managed until then with lifestyle alone. Pairing the amylin and GLP-1 pathways looks like a reasonable way to push past what a GLP-1 drug does by itself, though this trial did not test that comparison directly.
I want to stay honest about the limits. This was a placebo-controlled trial of 189 people with early-stage disease, run for 40 weeks, so I cannot say how CagriSema performs against today’s standard medicines in head-to-head use. Longer follow-up will be needed to see whether the weight stays off and whether benefits to the heart and kidneys follow. The trial was funded by Novo Nordisk, the manufacturer, and several authors are company employees. Early and promising is not the same as proven for the long haul.
Who this might help
This trial focused on adults whose type 2 diabetes was not adequately controlled by diet and exercise alone. That is a very common starting point. Many people in that group are told to add a medicine, and on this evidence CagriSema may become an option for someone who needs to lower blood sugar and lose a meaningful amount of weight at the same time.
The authors describe these findings as supporting CagriSema as a potential therapy for people with early-stage type 2 diabetes. That is a careful framing, and I would keep it. The right choice depends on your full health picture, so this is a conversation to have with your own doctor.
Practical Takeaways
- If diet and exercise alone are not controlling your type 2 diabetes, ask your doctor whether newer combination drugs like CagriSema could fit your treatment plan.
- Do not stop or change any current diabetes medicine on your own.
- Expect gastrointestinal side effects to be the most likely complaint. In this trial most adverse events were mild or moderate and gastrointestinal.
- Keep up healthy eating and movement, since every participant in this trial was on a diet and exercise background.
- Track both your blood sugar and your weight over time, since the value shown here is improving both at once.
Related Studies and Research
- Creatine for type 2 diabetes: a placebo-controlled trial
- Mediterranean diet plus exercise cuts diabetes risk by 31%
- Short sleep and poor diet: a double hit for type 2 diabetes risk
- Single-dose psilocybin vs placebo: first double-blind depression trial
FAQs
What is actually in a CagriSema injection?
Two drugs in one weekly subcutaneous shot: cagrilintide, an amylin receptor agonist, and semaglutide, a GLP-1 receptor agonist. This trial tested two strengths, 2.4 mg of each component and 1.0 mg of each component, against placebo. Semaglutide is already familiar from diabetes and weight-loss care. The combination is new, and less is known about long-term use.
How did each dose compare with placebo?
The 2.4 mg combination lowered HbA1c by 1.7 percentage points versus placebo and the 1.0 mg combination by 1.3 percentage points. For weight, the figures were 12.4 and 10.4 percentage points versus placebo. Adverse events were reported by 79 percent on the higher dose and 75 percent on the lower dose, against 66 percent on placebo.
How confident can I be in these results?
The trial was randomised, double-blind, and placebo-controlled, with participants, care providers, investigators, and outcome assessors masked within each dose level and visually identical injections used throughout. Both primary comparisons reached p below 0.0001. The main caveats are size and duration: 189 people followed for 40 weeks, in early-stage disease, funded by the manufacturer.
Bottom Line
This phase 3a trial found that a single weekly injection lowered HbA1c by 1.7 percentage points more than placebo and cut body weight by 13.8 percent over 40 weeks in adults whose type 2 diabetes was not controlled by diet and exercise. Side effects were mostly mild or moderate and gastrointestinal. By pairing the amylin and GLP-1 pathways, CagriSema produced a large effect on both blood sugar and weight in a short trial. Longer studies will show how well those gains hold up.
